Revvity's Q3 Net Income Halves Amid Soaring Interest Expenses

Ticker: RVTY · Form: 10-Q · Filed: Nov 4, 2025 · CIK: 31791

Sentiment: bearish

Topics: Earnings Miss, Profit Decline, Interest Expense, Cash Flow Concerns, Stock Buybacks, Life Sciences, Diagnostics

Related Tickers: RVTY

TL;DR

**Revvity's Q3 profit plunge and cash burn on stock buybacks is a red flag; sell on this weakness.**

AI Summary

Revvity, Inc. reported a net income of $46.652 million for the three months ended September 28, 2025, a significant decrease from $94.367 million in the prior year period. Total revenue increased slightly to $698.949 million from $684.049 million year-over-year, driven by a rise in service revenue to $125.724 million from $104.052 million. Product revenue, however, saw a slight decline to $573.225 million from $579.997 million. Operating income from continuing operations decreased to $81.896 million from $98.151 million, primarily due to a substantial increase in interest and other expense, net, which surged to $26.211 million from a net income of $2.206 million in the prior year. Basic earnings per share from continuing operations fell to $0.41 from $0.76. The company also experienced a net decrease in cash, cash equivalents, and restricted cash of $231.877 million for the nine months ended September 28, 2025, compared to an increase of $316.435 million in the same period last year, largely due to $652.530 million in common stock purchases.

Why It Matters

Revvity's substantial drop in net income and EPS, despite a modest revenue increase, signals potential margin pressures and rising financing costs that could concern investors. The significant increase in interest expense, net, from a gain to a $26.211 million expense, suggests a shift in the company's financial leverage or interest rate environment, impacting profitability. For employees, sustained financial performance is key for job security and growth opportunities. Customers might see impacts on product development or service quality if financial strains persist. In a competitive life sciences and diagnostics market, Revvity's reduced profitability could hinder its ability to invest in R&D and maintain its market position against rivals.

Risk Assessment

Risk Level: high — The company's net income for the three months ended September 28, 2025, decreased by over 50% to $46.652 million from $94.367 million in the prior year. This significant decline, coupled with a substantial increase in interest and other expense, net, to $26.211 million from a $2.206 million income, indicates deteriorating profitability and increased financial burden. Furthermore, the company used $652.530 million for common stock purchases, contributing to a $231.877 million net decrease in cash, cash equivalents, and restricted cash, raising liquidity concerns.

Analyst Insight

Investors should consider reducing their exposure to RVTY given the sharp decline in net income and the significant increase in interest expenses. The substantial cash outflow for stock repurchases amidst declining profitability warrants a cautious approach, suggesting capital might be better deployed elsewhere or retained for operational stability.

Financial Highlights

revenue
$698,949,000
operating Margin
11.7%
net Income
$46,652,000
eps
$0.40
gross Margin
46.4%
cash Position
$931,386,000
revenue Growth
+2.2%

Revenue Breakdown

SegmentRevenueGrowth
Product Revenue$573,225,000-1.2%
Service Revenue$125,724,000+20.8%

Key Numbers

Key Players & Entities

FAQ

What caused Revvity's net income to decrease in Q3 2025?

Revvity's net income decreased primarily due to a substantial increase in interest and other expense, net, which surged to $26.211 million in Q3 2025 from a net income of $2.206 million in Q3 2024, alongside a decline in operating income from continuing operations to $81.896 million from $98.151 million.

How did Revvity's revenue perform in the third quarter of 2025?

Revvity's total revenue for the three months ended September 28, 2025, increased slightly to $698.949 million from $684.049 million in the prior year period. This was driven by a 20.8% increase in service revenue to $125.724 million, offsetting a 1.2% decline in product revenue to $573.225 million.

What was Revvity's cash flow situation for the nine months ended September 28, 2025?

For the nine months ended September 28, 2025, Revvity reported a net decrease in cash, cash equivalents, and restricted cash of $231.877 million. This contrasts sharply with a net increase of $316.435 million in the same period of 2024, largely influenced by $652.530 million spent on common stock purchases.

What were the basic earnings per share for Revvity in Q3 2025?

Revvity's basic earnings per share from continuing operations for the three months ended September 28, 2025, was $0.41, a decrease from $0.76 in the corresponding period of 2024. The net income basic EPS was $0.40, down from $0.77.

What is the impact of increased interest expense on Revvity's profitability?

The significant increase in interest and other expense, net, to $26.211 million in Q3 2025 from a $2.206 million income in Q3 2024, directly reduced Revvity's income from continuing operations before income taxes by approximately $28.4 million, contributing substantially to the overall decline in net income.

How much did Revvity spend on common stock repurchases?

Revvity spent $652.530 million on purchases of common stock for the nine months ended September 28, 2025. This is a significant increase compared to $184.421 million spent in the same period of 2024.

What are the new accounting standards Revvity is evaluating?

Revvity is evaluating Accounting Standards Update 2025-06 (Targeted Improvements to the Accounting for Internal-Use Software), ASU 2024-03 (Disaggregation of Income Statement Expenses), and ASU 2023-09 (Improvements to Income Tax Disclosures). ASU 2023-09 is not expected to have a material impact on financial statement disclosures.

How did foreign currency translation adjustments affect Revvity's comprehensive income?

For the three months ended September 28, 2025, foreign currency translation adjustments resulted in a net loss of $22.322 million, significantly impacting comprehensive income. This contrasts with a gain of $109.774 million in the same period of 2024.

What were the total assets and liabilities for Revvity as of September 28, 2025?

As of September 28, 2025, Revvity reported total assets of $12,138,952 thousand and total liabilities of $4,763,056 thousand. This represents a decrease in total assets from $12,392,478 thousand at December 29, 2024, and an increase in total liabilities from $4,725,604 thousand.

What is Revvity's strategic outlook given the Q3 results?

While the filing does not explicitly state a strategic outlook, the Q3 results indicate a need for Revvity to address rising interest expenses and declining profitability. The company's continued investment in stock repurchases, despite negative cash flow, suggests a focus on shareholder returns, but this strategy may need re-evaluation if financial performance continues to deteriorate.

Risk Factors

Industry Context

Revvity, Inc. operates in the life sciences and diagnostics sectors, a competitive landscape characterized by innovation and consolidation. Key trends include the increasing demand for advanced diagnostic tools, personalized medicine, and integrated solutions for drug discovery and development. Companies in this space face pressure to invest heavily in R&D while managing complex supply chains and regulatory environments.

Regulatory Implications

As a global company, Revvity is subject to various regulations, including those related to product safety, data privacy (e.g., HIPAA, GDPR), and environmental standards. Changes in healthcare policies or international trade regulations could impact its operations and profitability. Compliance with these evolving regulations requires ongoing investment and vigilance.

What Investors Should Do

  1. Monitor the impact of increased interest expenses on future profitability.
  2. Analyze the drivers behind the decline in product revenue and the growth in service revenue.
  3. Evaluate the company's cash flow management and capital allocation strategy.
  4. Assess the company's ability to manage operating costs effectively.

Key Dates

Glossary

Continuing Operations
Refers to the ongoing business activities of a company that are expected to continue indefinitely, as opposed to discontinued operations which have been or will be disposed of. (Used to analyze the core profitability of Revvity, Inc., excluding any divested or planned-to-be-divested segments.)
Discontinued Operations
A component of a company's business that has been sold, abandoned, or otherwise disposed of, or is classified as held for sale. (The company reported a loss from discontinued operations in the current and prior periods, which is separated from the results of continuing operations.)
Other Comprehensive Income (Loss)
Includes gains and losses that are not reported in net income but are recorded directly in equity. Common items include foreign currency translation adjustments and unrealized gains/losses on certain investments. (Significant foreign currency translation adjustments impacted Revvity's total comprehensive income, showing a substantial loss in Q3 2025.)
Basic Earnings Per Share
Calculated by dividing net income by the weighted-average number of common shares outstanding during the period. (A key metric for investors to assess profitability on a per-share basis; it declined significantly for Revvity in Q3 2025.)
Diluted Earnings Per Share
Calculated similarly to basic EPS but also includes the effect of all dilutive potential common shares (e.g., stock options, convertible securities). (Provides a more conservative view of per-share profitability, also showing a decline for Revvity.)

Year-Over-Year Comparison

Compared to the prior year period, Revvity, Inc. reported a significant 50.6% decrease in net income for Q3 2025, falling to $46.652 million from $94.367 million, and a corresponding 46.1% drop in basic EPS from continuing operations to $0.41. While total revenue saw a modest 2.2% increase to $698.949 million, driven by strong service revenue growth, this was offset by a decline in product revenue and a substantial increase in interest and other expenses, which shifted from income to a significant expense. The company's cash position also deteriorated, with a net decrease of $231.877 million in cash for the nine months ended September 28, 2025, compared to a substantial increase in the prior year, largely due to significant common stock purchases.

Filing Stats: 4,652 words · 19 min read · ~16 pages · Grade level 15.4 · Accepted 2025-11-04 16:08:31

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Unaudited Financial Statements

Item 1. Unaudited Financial Statements 4 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Income 5 Condensed Consolidated Balance Sheets 6 Condensed Consolidated Statements of Stockholders' Equity 7 Condensed Consolidated Statements of Cash Flows 9 Notes to Condensed Consolidated Financial Statements 11

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Overview 25 Critical Accounting Policies and Estimates 25 Consolidated Results of Continuing Operations 26 Reporting Segment Results of Continuing Operations 28 Discontinued Operations 30 Liquidity and Capital Resources 30 Dividends 32 Effects of Recently Adopted and Issued Accounting Pronouncements 32

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 32

Controls and Procedures

Item 4. Controls and Procedures 32

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 34

Risk Factors

Item 1A. Risk Factors 34

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 42

Other Information

Item 5. Other Information 43

Exhibits

Item 6. Exhibits 43

Signatures

Signatures 44 3 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Unaudited Financial Statements

Item 1. Unaudited Financial Statements REVVITY, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended Nine Months Ended September 28, 2025 September 29, 2024 September 28, 2025 September 29, 2024 (In thousands, except per share data) Product revenue $ 573,225 $ 579,997 $ 1,742,983 $ 1,717,927 Service revenue 125,724 104,052 341,012 307,727 Total revenue 698,949 684,049 2,083,995 2,025,654 Cost of product revenue 280,731 256,551 813,878 770,196 Cost of service revenue 43,614 42,682 127,411 130,089 Total cost of revenue 324,345 299,233 941,289 900,285 Selling, general and administrative expenses 241,911 237,521 740,156 749,742 Research and development expenses 50,797 49,144 157,664 147,636 Operating income from continuing operations 81,896 98,151 244,886 227,991 Interest and other expense (income), net 26,211 ( 2,206 ) 68,169 6,423 Income from continuing operations before income taxes 55,685 100,357 176,717 221,568 Provision for income taxes 8,464 6,971 32,605 26,880 Income from continuing operations 47,221 93,386 144,112 194,688 (Loss) income from discontinued operations ( 569 ) 981 ( 1,275 ) ( 18,948 ) Net income $ 46,652 $ 94,367 $ 142,837 $ 175,740 Basic earnings per share: Income from continuing operations $ 0.41 $ 0.76 $ 1.22 $ 1.58 (Loss) income from discontinued operations ( 0.01 ) 0.01 ( 0.01 ) ( 0.15 ) Net income $ 0.40 $ 0.77 $ 1.21 $ 1.43 Diluted earnings per share: Income from continuing operations $ 0.41 $ 0.76 $ 1.22 $ 1.58 (Loss) income from discontinued operations ( 0.01 ) 0.01 ( 0.01 ) ( 0.15 ) Net income $ 0.40 $ 0.77 $ 1.21 $ 1.42 Weighted average shares of common stock outstanding: Basic 115,411 122,810 117,686 123,198 Diluted 115,463 123,026 117,735 123,336 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Table of Contents REVVITY, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INC

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing